Groupama Asset Managment Has $673,000 Stake in Stryker Corporation $SYK

Groupama Asset Managment decreased its position in Stryker Corporation (NYSE:SYK) by 8.1% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,845 shares of the medical technology company’s stock after selling 162 shares during the quarter. Groupama Asset Managment’s holdings in Stryker were worth $673,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of SYK. GAMMA Investing LLC raised its stake in shares of Stryker by 43,226.8% in the 1st quarter. GAMMA Investing LLC now owns 2,074,922 shares of the medical technology company’s stock valued at $772,390,000 after purchasing an additional 2,070,133 shares during the period. Nuveen LLC acquired a new stake in shares of Stryker in the first quarter valued at about $558,075,000. Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in shares of Stryker in the fourth quarter valued at about $154,140,000. Northern Trust Corp increased its position in shares of Stryker by 13.2% in the fourth quarter. Northern Trust Corp now owns 3,606,237 shares of the medical technology company’s stock valued at $1,298,426,000 after acquiring an additional 420,153 shares during the last quarter. Finally, Vanguard Group Inc. increased its position in shares of Stryker by 1.1% in the first quarter. Vanguard Group Inc. now owns 33,059,964 shares of the medical technology company’s stock valued at $12,306,572,000 after acquiring an additional 361,136 shares during the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Insider Activity

In other news, Director Ronda E. Stryker sold 200,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 6th. The stock was sold at an average price of $376.45, for a total transaction of $75,290,000.00. Following the completion of the sale, the director owned 3,222,108 shares in the company, valued at $1,212,962,556.60. The trade was a 5.84% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 5.90% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on SYK. Truist Financial set a $415.00 target price on Stryker and gave the company a “hold” rating in a research report on Monday, August 4th. JMP Securities reaffirmed a “market perform” rating on shares of Stryker in a research report on Monday, May 5th. Citigroup reaffirmed a “buy” rating and issued a $455.00 target price (up previously from $443.00) on shares of Stryker in a research report on Thursday, May 22nd. BTIG Research reaffirmed a “buy” rating on shares of Stryker in a research report on Monday, July 14th. Finally, Roth Mkm lifted their price target on Stryker from $405.00 to $456.00 and gave the stock a “buy” rating in a report on Friday, May 2nd. Fifteen equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, Stryker currently has a consensus rating of “Moderate Buy” and a consensus price target of $430.10.

Stryker Price Performance

Shares of NYSE SYK opened at $392.0050 on Thursday. The business’s 50 day moving average price is $387.09 and its two-hundred day moving average price is $379.54. The company has a market cap of $149.87 billion, a PE ratio of 51.92, a price-to-earnings-growth ratio of 2.83 and a beta of 0.91. The company has a quick ratio of 1.06, a current ratio of 1.78 and a debt-to-equity ratio of 0.70. Stryker Corporation has a twelve month low of $329.16 and a twelve month high of $406.19.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Thursday, July 31st. The medical technology company reported $3.13 earnings per share for the quarter, topping analysts’ consensus estimates of $3.07 by $0.06. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The firm had revenue of $6.02 billion for the quarter, compared to the consensus estimate of $5.92 billion. During the same quarter in the previous year, the business earned $2.81 earnings per share. The business’s revenue was up 11.1% compared to the same quarter last year. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. On average, analysts predict that Stryker Corporation will post 13.47 EPS for the current year.

Stryker Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th will be issued a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date is Tuesday, September 30th. Stryker’s payout ratio is currently 44.50%.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.